These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23290205)

  • 21. Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.
    Aupperle P
    Am J Alzheimers Dis Other Demen; 2006; 21(2):101-8. PubMed ID: 16634465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of antipsychotics in dementia depended on the definition of patients and outcomes: a meta-epidemiological study.
    Smeets CHW; Zuidema SU; Hulshof TA; Smalbrugge M; Gerritsen DL; Koopmans RTCM; Luijendijk HJ
    J Clin Epidemiol; 2018 Sep; 101():17-27. PubMed ID: 29782995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
    Pollock BG; Mulsant BH; Rosen J; Sweet RA; Mazumdar S; Bharucha A; Marin R; Jacob NJ; Huber KA; Kastango KB; Chew ML
    Am J Psychiatry; 2002 Mar; 159(3):460-5. PubMed ID: 11870012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study.
    Canevelli M; Adali N; Cantet C; Andrieu S; Bruno G; Cesari M; Vellas B;
    J Neurol; 2013 Jul; 260(7):1859-65. PubMed ID: 23504051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.
    Currier GW; Simpson GM
    J Clin Psychiatry; 2001 Mar; 62(3):153-7. PubMed ID: 11305699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
    Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
    Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.
    De Deyn PP; Rabheru K; Rasmussen A; Bocksberger JP; Dautzenberg PL; Eriksson S; Lawlor BA
    Neurology; 1999 Sep; 53(5):946-55. PubMed ID: 10496251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
    Rabinowitz J; Katz IR; De Deyn PP; Brodaty H; Greenspan A; Davidson M
    J Clin Psychiatry; 2004 Oct; 65(10):1329-34. PubMed ID: 15491235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Principal components analysis of agitation outcomes in Alzheimer's disease.
    Yesavage JA; Taylor JL; Friedman L; Rosenberg PB; Lazzeroni LC; Leoutsakos JS; Kinoshita LM; Perlow MJ; Munro CA; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
    J Psychiatr Res; 2016 Aug; 79():4-7. PubMed ID: 27115509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.
    Barak Y; Plopski I; Tadger S; Paleacu D
    Int Psychogeriatr; 2011 Nov; 23(9):1515-9. PubMed ID: 21492498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study.
    Lim HK; Kim JJ; Pae CU; Lee CU; Lee C; Paik IH
    Neuropsychobiology; 2010; 62(2):81-6. PubMed ID: 20523078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Actigraphy to Measure Symptoms of Agitation in Dementia.
    Knuff A; Leung RH; Seitz DP; Pallaveshi L; Burhan AM
    Am J Geriatr Psychiatry; 2019 Aug; 27(8):865-869. PubMed ID: 30952608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
    Workman RH; Orengo CA; Bakey AA; Molinari VA; Kunik ME
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):594-7. PubMed ID: 9447503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detecting agitation and aggression in persons living with dementia: a systematic review of diagnostic accuracy.
    Wong B; Wu P; Ismail Z; Watt J; Goodarzi Z
    BMC Geriatr; 2024 Jun; 24(1):559. PubMed ID: 38926638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
    Devanand DP; Pelton GH; Cunqueiro K; Sackeim HA; Marder K
    Int J Geriatr Psychiatry; 2011 Sep; 26(9):937-43. PubMed ID: 21845596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial.
    Mowla A; Pani A
    J Clin Psychopharmacol; 2010 Feb; 30(1):40-3. PubMed ID: 20075646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
    Ballard CG; Coate B; Abler V; Stankovic S; Foff E
    Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.